Hutchison China MediTech Ltd - Hong Kong-based biopharmaceutical company - China National Medical Products Administration granted priority review status to New Drug Application for savolitinib for the treatment of non-small call lung cancer. Also, has amended license & collaboration agreement with Eli Lilly & Co from 2013. Amendment covers expansion of Chi-Med's role in commercialisation of Elunate in China, under which Lilly will maintain exclusive commercialisation rights, and will continue to consolidate the sales of Elunate in China.
Current stock price: 413.00 pence
Year-to-date change: up 8.7%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Hutchmed (HCM)